CS/BSE/NSE/PR/2019-2020
July 09, 2019

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: 530239

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: SUVEN - EQ

Dear Sir/Madam,

Sub: Press Release

With reference to above subject, please find enclosed Press Release of our company titled **"Suven Life Sciences announces the delay in topline phase 2 study data of Masupirdine (SUVN-502)."**

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

K. Hanumantha Rao
Company Secretary

News Release

Suven Life Sciences announces the delay in topline phase 2 study data of *masupirdine* (SUVN-502)

HYDERABAD, INDIA (July 09, 2019) Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, today announced that the topline phase 2 study data of *masupirdine* (SUVN-502) to be presented at AAIC-2019 at Los Angeles on July 17, 2019 is delayed.

This phase 2, Proof-of-Concept (POC) study is a randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of *masupirdine* (SUVN-502) in moderate Alzheimer's Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer's disease patients.

There is an unanticipated delay in the *masupirdine* (SUVN-502) proof-of-concept phase 2 study outcome data availability in time for AAIC-2019 due to technical reasons.

Hence this study outcome results will not be presented at AAIC-2019 as originally planned.

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 finished *masupirdine* (SUVN-502), Phase 2 ready *samelisant* (SUVN-G3031), Phase1 completed SUVN-D4010 and SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has eight (8) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited
Registered Office: 8-2-334 l SDE Serene Chambers l 6th Floor Road No.5 l Avenue 7
Banjara Hills l Hyderabad – 500 034 l Telangana l India l CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com